Mumbai-based pharmaceutical major Wockhardt expects its novel drug portfolio to contribute over half of its total revenue within the next five years. This shift marks the culmination of a two-decade-long $800-million investment in advanced antibiotic research and development, aimed at establishing a highly differentiated anti-infective franchise rather than relying on a single blockbuster product.
The Novel Antibiotic Pipeline
Wockhardt’s multi-decade R&D strategy has yielded six novel anti-infective drugs designed to combat escalating global antimicrobial resistance (AMR).
Targeting Massive Clinical Demands in India
A primary driver for Wockhardt’s pipeline is the heavy systemic reliance on traditional, last-line antibiotics in India, which has historically accelerated bacterial resistance. The company is positioning its new candidates to complement or shield these existing treatments:
-
The Meropenem Challenge: Indian patients consume 25 million units of meropenem—a vital last-line antibiotic—every year. Wockhardt’s WCK 4282 is specifically being engineered to mitigate drug resistance associated with it.
-
Combination Overuse: The annual usage of meropenem alongside piperacillin-tazobactam (a standard penicillin-antibiotic combination) exceeds 75 million units across the country.
Leadership Insight: According to Wockhardt Chairman Habil Khorakiwala, building out this diversified, highly targeted portfolio provides the company with a sustainable clinical edge, ensuring they address multi-drug resistant strains across a broad spectrum of care rather than gambling on a single breakthrough molecule.
